BETA: Please send your feedback!
Ligand Pharmaceuticals
LGND:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
About
Biotechnology
Founded 1987
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| John W. Kozarich, PhD | Chairman | Male |
| Matthew W. Foehr | President & Chief Operating Officer | Male |
| Charles S. Berkman | Secretary, Vice President & General Counsel | Male |
| John L. Higgins | Chief Executive Officer & Director | Male |
| Ronald M. Evans, PhD | Founder | Male |
| Audrey Warfield-Graham | Vice President-Human Resources | Female |
| Vincent Antle, PhD | VP-Technical Operations & Quality Assurance | Male |
| Matthew E. Korenberg | CFO, Principal Accounting Officer & VP-Finance | Male |
Mindful Investing Summary
Ligand Pharmaceuticals - Competitors and Related Companies
How Ligand Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.
Ligand Pharmaceuticals
LGND:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
Spectrum Pharmaceuticals
SPPI:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
Baxter International
BAX:NYS
Medical Specialties
—
LARGE cap
(—)
—
since start of 2020
—
GTx
GTXI:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
Amgen
AMGN:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2020
—
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—